

Review of Coronary Heart Disease Risk in HIV Treatment Roundtable #2: Mechanism and Pharmacodynamics Explaining Increased Coronary Heart Disease (CHD)

Artemis Hotel Amsterdam, The Netherlands May 12, 2010

Quazi Ataher, MBBS, MHS, PhD Pfizer Inc.

Franck Boccara, MD, PhD Saint Antoine University Hospital

Nisha Chandra-Strobos, MDJohns Hopkins University School of Medicine

Dominique Costagliola, PhD INSERM U943

Chris Duncombe, MDAntiretroviral Treatment and HIV Care
Department of HIV/AIDS

Courtney Fletcher, PharmDCollege of Pharmacy
University of Nebraska Medical Center

Filip Josephson, MD, PhD Swedish Medical Products Agency Amy Keller, BS
Arcara Keller LLC

Karin Klingman, MD Division of AIDS Alan Landay, PhD

Rush University Medical Center

Sylvie Lang, Master

INSERM

Michael Lederman, MD

Case Western Reserve University

Paddy Mallon, MB BCh BAO FRACP FRCPI PhD

University College Dublin

Kendall Marcus, MD

Food and Drug Administration

Veronica Miller, PhD

Forum for Collaborative HIV Research

Ivona Pandrea, MD, PhD

University of Pittsburgh

Maya Petersen, MD, PhD

University of California, Berkeley

Bill Powderly, MD

University College Dublin

Peter Reiss, MD, PhD

Academic Medical Center, University of Amsterdam

Caroline Sabin, PhD

University College London

Neil Shortman, CBiol MSB

ViiV Healthcare

Jur Strobos, MD, JD

Forum for Collaborative HIV Research

Russell Tracy, PhD University of Vermont

Jean Tschampa, PharmD Abbott

Mark van der Laan, PhD University of California, Berkeley Paige Williams, PhD Harvard School of Public Health